Abstract 551P
Background
The use of immune checkpoint inhibitors (ICI) has transformed the management of non-small cell lung cancer (NSCLC). With improved cancer outcomes have come increased auto-immune toxicities, which could affect any organ system. We investigated the incidence and outcomes of immune-related adverse events (irAE) in a large cohort of NSCLC patients.
Methods
Medical records from a metropolitan cancer centre in the AUstralian Registry and biObank of thoRAcic cancers (AURORA) registry were reviewed. Kaplan Meier analysis was used for survival estimates. Risk factors were tested using Fishers Exact test and logistic regression. False discovery rate of 5% was used to correct for multiple testing.
Results
Between 2013-2021, 449 patients received ICI. The median age was 65 years, 61% were male. Most (91%) had an ECOG of 0-1, 68% had metastatic disease at diagnosis, and 70% had adenocarcinoma. ICI was given as first line treatment in 47% of patients, and 22% had curative intent therapy. irAE were identified in 106 patients (24%). Most frequent was pneumonitis in 34 patients (incidence 7.6%); followed by colitis in 21 (4.5%), acute kidney injury in 19 (4.2%), thyroid disorders in 14 (3.1%), hepatitis in 12 (2.7%), skin toxicity in eight (1.8%), myositis in four (0.9%) and cardiac disorders and hypoadrenalism in three (0.7%) each. Toxicities noted twice included: arthropathy, hypoadrenalism, encephalitis, blood dyscrasias, diabetes, and ocular toxicities. Diabetes, gastritis and enteritis were identified in one patient each. Nineteen (4.2%) patients had two toxicities, one patient recorded three toxicities and one had four. No relationship was found between irAE and ICI combination therapy, smoking, age, performance status, or sex. The rate of pneumonitis was higher in those with airways disease than in those without (OR 14.81, 95% CI 6.64-33.59, P<0.01). Median overall survival in those with irAE was 18.7 months, versus 9.2 months in those without (HR 0.54, 95%CI 0.42-0.70, P=<0.01).
Conclusions
In a real word cohort, immune-related toxicities were similar to those reported in the literature. The development of irAE was associated with improved survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. M. Alexander: Financial Interests, Personal, Advisory Board: BMS/Pfizer. T. John: Financial Interests, Personal, Invited Speaker, Speaker tour Vietnam: AstraZeneca; Financial Interests, Personal, Invited Speaker, CTIO: Merck Sharp Dohme; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Bayer, Specialised Therapeutics; Financial Interests, Institutional, Advisory Board: Roche, Novartis, Pfizer, Amgen, Takeda, PharmaMar; Financial Interests, Personal, Other, Speaker/Chair: ACE Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
5P - Clinicopathologic features and genomic profiling of occult breast cancer
Presenter: Liansha Tang
Session: Poster Display
Resources:
Abstract
6P - Tumor cell-released autophagosomes (TRAPs) promote lung metastasis through inducing PD-L1 high expression of pulmonary vascular endothelial cells (PVECs) in breast cancer
Presenter: Xuru Wang
Session: Poster Display
Resources:
Abstract
7P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: Xiaohe Zhou
Session: Poster Display
Resources:
Abstract
9P - Clinicopathological features and prognosis of mucinous breast cancer: A retrospective analysis of 358 patients in Vietnam
Presenter: Hoai Hoang
Session: Poster Display
Resources:
Abstract
10P - Comparison of 28-gene and 70-gene panel in risk-prediction of Chinese women with early-stage HR-positive and HER2-negative breast cancer
Presenter: Lei Lei
Session: Poster Display
Resources:
Abstract
11P - Multimodal analysis of methylation and fragmentomic profiles in plasma cell-free DNA for differentiation of benign and malignant breast tumors
Presenter: Hanh Nguyen
Session: Poster Display
Resources:
Abstract
12P - Plasma cell-free mRNA profiles enable early detection of breast cancer
Presenter: Chi Nguyen
Session: Poster Display
Resources:
Abstract
13P - Relationship of distress and quality of life with gut microbiome composition in newly diagnosed breast cancer patients: A prospective, observational study
Presenter: Chi-Chan Lee
Session: Poster Display
Resources:
Abstract
14P - Classification of molecular subtypes of breast cancer in whole-slide histopathological images using a novel deep learning algorithm
Presenter: Hyung Suk Kim
Session: Poster Display
Resources:
Abstract
15P - The regulation of pregnenolone in breast cancer
Presenter: Hyeon-Gu Kang
Session: Poster Display
Resources:
Abstract